VCYT Earnings Prediction
The chart below shows how VCYT performed 10 days before and after its earnings report, based on data from the past quarters. Typically, VCYT sees a -0.68% change in stock price 10 days leading up to the earnings, and a +10.38% change 10 days following the report. On the earnings day itself, the stock moves by +1.34%. This data can give you a slight idea of what to expect for the next quarter's release.
VCYT Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
115.86M
28.58%
1.25%
Gross Margin
67.43%
6.29%
0.16%
Operating Margin
10.53%
200.00%
161.29%
Net Margin
13.08%
139.79%
161.08%
EPS
0.19
146.34%
171.43%
No Data Available
VCYT Earnings Analysis
Veracyte, Inc. Corporation (VCYT.O) Earnings Conference Call
Positive
Q3 Revenue Increase: Q3 revenue totaled $115.9 million, growing 29% year-over-year.
Testing Revenue Surge: Testing revenue grew an incredibly robust 34% compared to the prior year period, driven by strong volume and ASP improvements.
Sustained Testing Revenue Growth: Q3 represents our ninth consecutive quarter of 25% or greater testing revenue growth, demonstrating clearly the durability of our testing portfolio.
Record Test Deliveries Growth: We delivered a record 21,250 tests during the third quarter, up 36% year-over-year with growth across all NCCN localized risk categories.
Cash Generation and Reserves: We generated $38 million of cash in the quarter, driven primarily by $30 million of cash from operations and ended Q3 with $274.1 million of cash and cash equivalents.
Negative
Revenue Decline Analysis: Q3 revenue totaled $115.9 million, a decrease of 21% year-over-year as we continue to work through supply challenges.
Quarterly Revenue Decline: Testing revenue during the quarter was $109.5 million, a decrease of 21% year-over-year, driven by Decipher and Afirma revenue growth of 48% and 19%, respectively.
Testing Volume Decline: Total testing volume was approximately 36,800 tests, down 21% year-over-year as we continue to manage demand.
Biopharmaceutical Revenue Decline: Biopharmaceutical and other revenue was $3.1 million, down 23% year-over-year.
Operating Expenses Increase: Non-GAAP operating expenses were up 11% year-over-year at $57.6 million.
VCYT FAQs
How does VCYT typically perform around its earnings report dates?
Is Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
VCYT Earning Call Sentiment
Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
VCYT.O
-4.56%Positive
The earnings call presents a mixed picture. Financial performance shows strong testing revenue growth and raised guidance, but product revenue is down due to supply challenges. The lack of a shareholder return plan and competitive pressures are concerns. While management is optimistic about future growth, the Q&A reveals uncertainties, especially regarding supply chain impacts and growth specifics. The raised guidance and strong testing growth are positives, but these are offset by supply chain issues and competitive pressures, resulting in a neutral sentiment.
